Bibliographie - 184 - Stabilis 4.0

Last update :
08/05/2024

References

References 184

Type :

Journal

Research teams :

Athens - University of Georgia, College of Pharmacy

Authors :

Stewart JT, Warren FW, King DT, Fox JL.

Title :

Stability of ondansetron hydrochloride and five antineoplasic medications.

Reference :

Am J Health-Syst Pharm ; 53: 1297-1300. 1996

Level of Evidence :

Level of evidence C+

AideBibliographie

Physical stability :

Visual examination

Particle counting

Chemical stability :

Stability defined as 95% of the initial concentration

High Performance Liquid Chromatography - Diode Array detector (HPLD-DAD)

Other methods :

PH measurement

Comments :

Stability indicating capability inadequately assessed

Results with high coefficient of variation or not provided, or lack of duplicate analysis of each point

No comments for the degradation products

List of drugs

Injection

Cytarabine

Anticancer drug

	0,2 mg/ml	+ Ondansetron hydrochloride	0,03 mg/ml	+
	0,2 mg/ml	+ Ondansetron hydrochloride	0,3 mg/ml	+
	40 mg/ml	+ Ondansetron hydrochloride	0,03 mg/ml	+
	40 mg/ml	+ Ondansetron hydrochloride	0,3 mg/ml	+

Injection

Dacarbazine

Anticancer drug

	3 mg/ml	+ Ondansetron hydrochloride	0,03 mg/ml	+
	3 mg/ml	+ Ondansetron hydrochloride	0,3 mg/ml	+
	1 mg/ml	+ Ondansetron hydrochloride	0,3 mg/ml	+
	1 mg/ml	+ Ondansetron hydrochloride	0,03 mg/ml	+

Injection

Doxorubicin hydrochloride

Anticancer drug

	0,1 mg/ml	+ Ondansetron hydrochloride	0,03 mg/ml	+
	0,1 mg/ml	+ Ondansetron hydrochloride	0,3 mg/ml	+
	2 mg/ml	+ Ondansetron hydrochloride	0,03 mg/ml	+
	2 mg/ml	+ Ondansetron hydrochloride	0,3 mg/ml	+

Injection

Etoposide

Anticancer drug

	0,4 mg/ml	+ Ondansetron hydrochloride	0,03 mg/ml	+
	0,4 mg/ml	+ Ondansetron hydrochloride	0,3 mg/ml	+
	0,1 mg/ml	+ Ondansetron hydrochloride	0,3 mg/ml	+
	0,1 mg/ml	+ Ondansetron hydrochloride	0,03 mg/ml	+

Injection

Methotrexate sodium

Anticancer drug

	6 mg/ml	+ Ondansetron hydrochloride	0,3 mg/ml	+
	0,5 mg/ml	+ Ondansetron hydrochloride	0,3 mg/ml	+
	0,5 mg/ml	+ Ondansetron hydrochloride	0,03 mg/ml	+
	6 mg/ml	+ Ondansetron hydrochloride	0,03 mg/ml	+

Injection

Ondansetron hydrochloride

Antiemetic

	0,03 mg/ml	+ Cytarabine	0,2 mg/ml	+
	0,03 mg/ml	+ Cytarabine	40 mg/ml	+
	0,3 mg/ml	+ Cytarabine	40 mg/ml	+
	0,3 mg/ml	+ Cytarabine	0,2 mg/ml	+
	0,03 mg/ml	+ Dacarbazine	3 mg/ml	+
	0,3 mg/ml	+ Dacarbazine	3 mg/ml	+
	0,3 mg/ml	+ Dacarbazine	1 mg/ml	+
	0,03 mg/ml	+ Dacarbazine	1 mg/ml	+
	0,3 mg/ml	+ Doxorubicin hydrochloride	0,1 mg/ml	+
	0,03 mg/ml	+ Doxorubicin hydrochloride	2 mg/ml	+
	0,03 mg/ml	+ Doxorubicin hydrochloride	0,1 mg/ml	+
	0,3 mg/ml	+ Doxorubicin hydrochloride	2 mg/ml	+
	0,03 mg/ml	+ Etoposide	0,4 mg/ml	+
	0,3 mg/ml	+ Etoposide	0,4 mg/ml	+
	0,3 mg/ml	+ Etoposide	0,1 mg/ml	+
	0,03 mg/ml	+ Etoposide	0,1 mg/ml	+
	0,3 mg/ml	+ Methotrexate sodium	6 mg/ml	+
	0,3 mg/ml	+ Methotrexate sodium	0,5 mg/ml	+
	0,03 mg/ml	+ Methotrexate sodium	0,5 mg/ml	+
	0,03 mg/ml	+ Methotrexate sodium	6 mg/ml	+

Stability of mixtures

Polyvinyl chloride

Glucose 5%

21°C-23°C

Light

Ondansetron hydrochloride	0,03 & 0,3 mg/ml
Cytarabine	0,2 & 40 mg/ml

48

Hour

Polyvinyl chloride

Glucose 5%

21°C-23°C

Light

Doxorubicin hydrochloride	0,1 & 2 mg/ml
Ondansetron hydrochloride	0,03 & 0,3 mg/ml

48

Hour

Polyvinyl chloride

Glucose 5%

21°C-23°C

Light

Ondansetron hydrochloride	0,03 & 0,3 mg/ml
Etoposide	0,1 & 0,4 mg/ml

48

Hour

Polyvinyl chloride

Glucose 5%

21°C-23°C

Light

Ondansetron hydrochloride	0,03 & 0,3 mg/ml
Methotrexate sodium	0,5 & 6 mg/ml

48

Hour

Mentions Légales